In a meta-analysis of more than 56,000 patients with T2DM, GLP-1 RAs showed statistically significant reductions in MACE (by 12%) and all-cause mortality (by 12%), as well as a broad renal composite outcome (by 17%) and a lower risk of hospitalization for HF (by 9%) [173]. The gene discussed is GLP1R; the disease is hydrops fetalis.